Delivery Order SPE2DB20D1047-SPE2DB25FF72G
Award Date 7/16/25
Potential Completion Date 8/6/25
Potential Value $16K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $16,244.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (7-count packaging) on September 9, 2025, with a completion date of September 30, 2025. This firm fixed-price delivery order represents a non-competitive set-aside arrangement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7) under a firm fixed-price contract valued at $8,122.48, with an ultimate completion date of October 21, 2025. This non-competitive delivery order was issued on September 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used in cancer treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7) on June 2, 2025, with an ultimate completion date of June 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's Conshohocken, Pennsylvania location. Ibrance is a prescription oncology medication used in breast cancer treatment, reflecting the Defense...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,236.16 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg tablets (7-count units) on August 25, 2025, with completion scheduled for September 16, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity of seven units). This firm fixed-price delivery order, issued on July 25, 2025, carries an ultimate completion date of August 15, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance (palbociclib) is a cyclin-dependent...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on July 14, 2025, with completion scheduled for August 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used in cancer treatment, reflecting the critical...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for Ibrance 75 mg capsules (21-count unit) on July 22, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used in cancer treatment, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ibrance 125 mg capsules (21-count packages) with a ceiling value of $8,118.08. This firm fixed-price delivery order, which is expected to be completed by June 24, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription cancer treatment medication,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 100 mg tablets (7-count packaging) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with an ultimate completion date of October 9, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The award was made through open competition with no set-aside designation, and fulfillment will...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ibrance 100 mg capsules (21-count packages) with a ceiling value of $16,244.96. This firm fixed-price delivery order, with an ultimate completion date of September 29, 2025, represents a non-competitive set-aside contract and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ibrance is a brand-name oncology medication used...